GlassScriptPhysician profile
Mirza Omari
NPI 1194214163
$1,197.76
in general payments reported to CMS, 2019-2025
8 companies · $631 in 2025
The $631 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $99.98 · 2024: $467 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $287.29 | 2023-2024 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $279.61 | 2024-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $230.18 | 2024-2025 | |
| Celgene Corporation | $151.24 | 2024-2025 | Zeposia |
| Biogen, INC. | $115.14 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Tg Therapeutics, INC. | $54.97 | 2025 | |
| Cycle Pharmaceuticals INC | $46.53 | 2025 | Tascenso Odt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirza Omari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.